摘要:
A medicament for treatment of hepatic ascites and a preparation method therefor. Shiraia bambusicola, Gleditsia sinensis thorn, Bubalus bubalis horn, Bambusae Caulis in Taeniam, Angelica pubescens, Schisandra chinensis, Radix Puerariae, Hedyotis diffusa are used as active ingredients. Glycyrrhiza uralensis, lotus leaf, Cassia obtusifolia seed, Pseudostellaria heterophylla, Panax quinquefolius, Eucommia ulmoides, Paeonia lactiflora, Sophora flavescens are used as excipients. Provided is efficacy in liver preservation, detoxification, blood cleansing, and vital energy supplementation. By means of syndrome differentiation and classification, treatment is administered according to syndromes, thus improving efficacy. Improved efficacy and recovery effects are provided for hepatic ascites caused by hepatitis B and cirrhosis.
摘要:
Compositions and preparation method thereof, said compositions comprise herb extract from a mixture comprising Cyclocarya paliurus leaf and one or two herbs selected from the group consisting of Puerariae lobatae Radix and Polygonati odorati Rhizoma, said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia.
摘要:
A composition, a health functional food or a treatment method of the present invention has a remarkable cranial nerve cell protection effect and simultaneously has a sensorimotor function recovery promotion effect and a body weight increasing effect. Accordingly, the present invention has effects of preventing stroke or neurodegenerative diseases, protecting cranial nerve cell cells over the mid to long term immediately after the onset of disease, promoting the recovery of a sensorimotor function reduced by stroke and neurodegenerative diseases, and increasing a reduced body weight. Therefore, the present invention can be used for effectively preventing, treating or managing stroke and neurodegenerative diseases.
摘要:
The present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema containing a mixed extract of Hedera helix leaves and Coptis chinensis as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition and a health functional food composition for prevention, treatment or amelioration of diabetic complications or angioedema further containing an extract of Rheum palmatum , Puerariae radix, Ginkgo leaves, Cassiae semen , blueberry, bilberry, raspberry, or grape seeds as an active ingredient, in addition to the mixed extract of Hedera helix leaves and Coptis chinensis.
摘要:
A tablet composition containing a Chinese orthodox medicine extract, cellulose glycolic acid and sodium hydrogencarbonate. It is preferable that the composition further contains silicic anhydride. A process for producing a tablet composition containing a Chinese orthodox medicine extract which involves the step of adding silicic anhydride and water to the Chinese orthodox medicine extract powder and granulating the mixture under stirring and the step of adding cellulose glycolic acid and sodium hydrogencarbonate to the granulated matter thus obtained. The tablet composition containing a Chinese orthodox medicine extract is excellent in disintegration and elution properties.
摘要:
The invention provides cosmetics or dermatological compositions comprising plant extract or whey extract having an action to potentiate laminin 5 productivity in the epidermal cells. They have mainly the action and efficacy to prevent or improve aging in the skin.
摘要:
The present invention relates to a method of preventing and/or treating diabetes type 2, also, it relates to a method of augmenting Glut4 phosphorylation and Glut4 translocation to a target cell membrane to enhance insulin signal in a signal transduction pathway; further, it relates to a simplified and inexpensive process of obtaining extract and thereafter selectively, its active n-butanol fraction and active molecule Lupinoside PA (LPA4), useful in preventing and/or treating diabetes type 2; and lastly, a pharmaceutical composition thereof.